



(51) International Patent Classification:

C07D 231/56 (2006.01) A61K 31/404 (2006.01)
C07D 403/06 (2006.01) A61K 31/416 (2006.01)
C07D 409/06 (2006.01) A61P 31/04 (2006.01)
C07D 209/08 (2006.01)

(21) International Application Number:

PCT/EP2014/078384

(22) International Filing Date:

18 December 2014 (18.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13198338.9 19 December 2013 (19.12.2013) EP


(71) Applicant: ACTELION PHARMACEUTICALS LTD
[CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).(72) Inventors: HUBSCHWERLEN, Christian; 15, rue de la
gendarmerie, F-68480 Durmenach (FR). OCHALA,
Etienne; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse
16, CH-4123 Allschwil (CH). SPECKLIN, Jean-Luc; c/o
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-
4123 Allschwil (CH). SURIVET, Jean-Philippe; c/o Ac-
telion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123
Allschwil (CH).(74) Agent: RUHLMANN, Eric; c/o Actelion Pharmaceuticals
Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: ANTIBACTERIAL 1H-INDAZOLE AND 1H-INDOLE DERIVATIVES



(57) **Abstract:** The invention relates to antibacterial compounds of formula (I) wherein X is N or CH; R¹ is H or halogen; R² is al-
kynyloxy or the group M; R³ is H or halogen; M is one of the groups M^A and M^B represented below wherein A is a bond, CH₂CH₂,
CH=CH or C≡C; R^{1A} is H or halogen; R^{2A} is H, alkoxy or halogen; R^{3A} is H, alkoxy, hydroxyalkoxy, alkoxyalkoxy, thioalkoxy, tri-
fluoromethoxy, amino, hydroxyalkyl, 2-hydroxyacetamido, 1-aminocyclopropyl, 1-hydroxymethyl- cycloprop-1-yl, 1-((phos-
phonooxy)methyl)cyclopropyl, 1-(((dimethylglycyl)oxy)methyl)cyclopropyl, *trans*-2-hydroxymethyl-cycloprop- 1-yl, 1,2-dihydroxy
ethyl, 3-hydroxyoxetan-3-yl, 3-(hydroxyalkyl)oxetan-3-yl, 3-aminooxetan- 3-yl, 3-hydroxythietan-3-yl, morpholin-4-ylalkoxy, mor-
pholin-4-yl-alkyl, oxazol-2-yl or [1,2,3]triazol-2-yl; and R^{1B} is hydroxyalkyl, dihydroxyalkyl, aminoalkyl, 1-hydroxymethyl-cyclop-
rop- 1-yl, 1-aminomethyl-cycloprop- 1-yl, iraws-2-hydroxymethyl- cycloprop-1-yl, 3-hydroxyoxetan-3-yl, 3-hydroxythietan-3-yl, 1
-(2-hydroxyacetyl)azetidin- 3-yl, 1-(2-aminoacetyl)azetidin-3-yl, 1-glycylazetidin-3-yl, 1-(2-amino- 2-methylpropanoyl)azetidin-3-yl,
3-(2-aminoacetamido)cyclopentyl, *trans*-(*cis*-3,4-dihydroxy)-cyclopent-1-yl or 3-hydroxymethylbicyclo [1,1, 1]pentan-1-yl; and
salts thereof.

WO 2015/091741 A1



Published:

— *with international search report (Art. 21(3))*